The findings from the BATURA clinical trial were presented at the 2025 ACAAI Annual Scientific Meeting.
ACAAI Annual Scientific Meeting - American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Depemokimab shows significant improvements in asthma symptoms and peak expiratory flow, supporting its twice-yearly use for severe asthma management.
Advertisement
About 41% and 30% of patients with chronic spontaneous urticaria (CSU), respectively, achieved well-controlled disease status and complete response when treated with dupilumab.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Influenza Hospitalizations in Children Reveal Significant Non-respiratory Complications
2
Weight Loss Drugs On the Horizon: What Pharmacists Should Know
3
Kratom Controversies: Exploring Use and Regulation
4
FDA Approves Aflibercept Injection to Treat Patients With Macular Edema Following RVO
5
